The mechanism seems to be independent of the catalytic activity, since these effects were not mimicked by systemic DPP-4 inhibition (73, 82), and it was suggested that soluble DPP-4 interacted with caveolin-1 on adipose tissue macrophages, the down-stream effects of which combined with actions of other pro-inflammatory molecules such as factor Xa, to lead to activation of the inflammatory signaling pathway (83) (Figure 3)
While Gasoyan expressed hope that this might help promote conversations between clinicians and individuals: For patients who need to stop their GLP-1 RA or dual receptor agonist medication, there are several alternative obesity treatments available
Clinical observations describing reduced protein intake, variability in lean mass trajectories, and micronutrient insufficiency during pharmacologically induced weight loss [40, 75, 94, 95] suggest that long-term metabolic stability may become sensitive to substrate availability even in the absence of overt deficiency
But combination therapy should only be done under medical supervision to make sure dosing and timing are right for your body
Manufacturers are in the process of making new GLP-1s that are easier to produce, store, and administer
This combination can help boost metabolism, enhance fat breakdown, and promote weight loss